Table 1.
Technology | Sample Processing | Amplification Method | Cas Effector Protein | Assay Readout | Companion Smartphone App | SARS-CoV-2 Target Gene | Patient Sample Validation |
Reference | |||
---|---|---|---|---|---|---|---|---|---|---|---|
No. of + Samples | No. of – Samples | Sensitivity (%) | Specificity (%) | ||||||||
DETECTR | Nucleic acid extraction | RT-LAMP | Cas12 | Lateral flow | E | 36 | 42 | 95 | 100 | Broughton et al., 2020b | |
N | 36 | 42 | 95 | 100 | |||||||
CARMEN | Nucleic acid extraction | PCR | Cas13 | Fluorescent | Orf1ab | n.d. | n.d. | n.a. | n.a. | Ackerman et al. 2020 | |
CASdetec | Chemical treatment | RT-RPA | Cas12 | Fluorescent | Orf1ab | n.d. | n.d. | n.a. | n.a. | Guo et al. 2020 | |
SHERLOCK | Nucleic acid extraction | RT-RPA | Cas13 | Fluorescent | S | 81 | 453 | 100 | 100 | Patchsung et al., 2020 | |
Lateral flow | S | 81 | 453 | 97 | 100 | ||||||
CRISPR-COVID | Nucleic acid extraction | RT-RPA | Cas13 | Fluorescent | Orf1ab | 52 | 36 | 100 | 100 | Hou et al. 2020 | |
CRISPR-FDS-v1.0 | Nucleic acid extraction | RT-RPA or RT-PCR | Cas12 | Fluorescent | N or Orf1ab | 19 | 10 | 100 | 71.4 | Huang et al. 2020 | |
CRISPR/Cas12a-NER | Nucleic acid extraction | RT-RPA | Cas12 | Fluorescent | E | 16 | 15 | 100 | 100 | Wang et al. 2020 | |
STOPCovidv1 | Chemical and heat treatment | RT-LAMP | Cas12 | Lateral flow | N | 62 | 22 | 84 | 100 | Joung et al. 2020 | |
STOPCovidv2 | Chemical, heat, and magnetic treatment | Fluorescent | N | 200 | 200 | 93.1 | 98.5 | ||||
iSCAN | Nucleic acid extraction | RT-LAMP | Cas12 | Fluorescent | E | 26 | 5 | 50 | 100 | Ali et al. 2020 | |
Fluorescent | N | 26 | 5 | 88 | 100 | ||||||
Lateral flow | N | 21 | 3 | 81 | 100 | ||||||
Electric field-mediated SARS-CoV-2 detection | Chemical and heat treatment followed by isotachophoresis extraction | RT-LAMP | Cas12 | Fluorescent | N | 32 | 32 | 90.6 | 100 | Ramachandran et al. 2020 | |
E | 32 | 32 | 90.6 | 100 | |||||||
SHINE | Chemical and heat treatment (HUDSON) | RT-RPA | Cas13 | Fluorescent | X | Orf1ab | 42 | 40 | 93.3 | 100 | Arizti-Sanz et al. 2020 |
Lateral flow | Orf1ab | 4 | 3 | 100 | 100 | ||||||
Contamination-free, visual Cas12 assay | Nucleic acid extraction | RT-LAMP | Cas12 | Fluorescent | X | Orf1ab | 7 | 3 | 100 | 100 | Chen et al. 2020 |
E | n.d. | n.d. | n.a. | n.a. | |||||||
N | n.d. | n.d. | n.a. | n.a. | |||||||
Direct, Cas13a detection | Nucleic acid extraction | n.a. | Cas13 | Fluorescent | X | E & N combined | 5 | 1 | 100 | 100 | Fozouni et al. 2020 |
CRISPR-FDS-v2.0 | Chemical and heat treatment of saliva | RT-RPA | Cas12 | Fluorescent | Orf1ab | 44 | 59 | 100 | 100 | Ning et al. 2020 | |
Fluorescent | X | Orf1ab | 44 | 59 | 97.7 | 100 | |||||
Chemical and heat treatment of nasal swab | RT-RPA | Cas12 | Fluorescent | Orf1ab | 27 | 76 | 100 | 97.7 | |||
Fluorescent | X | Orf1ab | 27 | 76 | 100 | 98.7 |